Autonomix Medical Appoints Former Medtronic Chief Regulatory Counsel Sandra Cohen Kalter to Board of Directors
Appointment adds more than four decades of MedTech leadership, FDA regulatory and strategic transaction experience, including work supporting renal denervation and other category-defining technologies
Covered in this story
What has happened since
- Medtronic is up 2.2% since this was published, 34 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Medtronic
- Mizuho: $92.2 → $115 by Sep 2027 · Outperform via Investing.com
- Stifel: $92.2 → $95 by Sep 2027 · Hold via Investing.com
- Needham: $92 → $114 by Sep 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $MDT yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Medtronic →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.